Related Experiment Video

Updated: Sep 18, 2025

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
07:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

2.7K

Endostatin-based anti-angiogenic therapy and immune modulation: mechanisms and synergistic potential in cancer

JingTao Sun1, Simeng Ren2, QingYun Zhao1

  • 1Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.

Frontiers in Immunology
|June 27, 2025
PubMed

Insights

Endostatin therapy shows promise for cancer by inhibiting tumor blood vessel growth and improving immune response. Research explores novel strategies to enhance its effectiveness and overcome delivery challenges for better cancer treatment.

Area of Science:

  • Oncology
  • Cancer Biology
  • Immunology

Background:

  • Cancer is a major health issue, fueled by tumor angiogenesis and immune evasion.
  • Endostatin, a collagen XVIII fragment, targets both angiogenesis and the immunosuppressive tumor microenvironment (TME).
  • Recombinant human endostatin (rhEs) has shown clinical promise but faces limitations in efficacy and delivery.

Purpose of the Study:

  • To review endostatin's mechanisms in inhibiting angiogenesis and modulating the immune system.
  • To evaluate the clinical efficacy of endostatin in solid tumors.
  • To explore innovative strategies for overcoming translational barriers and enhancing endostatin's therapeutic potential.

Main Methods:

  • Literature review synthesizing current knowledge on endostatin.
  • Analysis of endostatin's dual mechanisms of action.
  • Evaluation of clinical data and emerging therapeutic strategies.

Main Results:

  • Endostatin effectively suppresses tumor angiogenesis and reprograms the immunosuppressive TME.
  • Emerging strategies like nanotechnology and combination therapies aim to improve rhEs efficacy.
  • Synergistic opportunities exist with radiotherapy, chemotherapy, and immunotherapy.

Conclusions:

  • Endostatin is a promising dual-targeting therapeutic agent for cancer.
  • Overcoming delivery limitations and transient efficacy is crucial for clinical success.
  • Harnessing endostatin's potential requires innovative strategies and combination approaches for precision cancer therapy.
Keywords:
angiogenesisdrug deliveryendostatinimmune modulationpeptide derivatives

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

9.9K
Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

1.2K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
667
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.9K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K